LEXX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 22:00):

Stats
Dagens volum	362 642
Gjennomsnittsvolum	513 345
Markedsverdi	43.20M
EPS	$0 ( 2024-04-12 )
Neste inntjeningsdato	( $-0.130 ) 2024-07-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.15
ATR14	$0.0390 (1.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Cabatuan Nelson	Sell	200 000	Stock Options
2023-10-26	Carle Vanessa	Buy	12 500	Stock Options
2023-10-26	Docherty John Martin	Buy	30 000	Stock Options
2023-10-26	Bunka Christopher	Buy	30 000	Stock Options
2023-07-25	Baxter Nicholas W	Buy	5 000	Stock Options

INSIDER POWER
-25.36
Last 99 transactions
Buy: 4 974 810 \| Sell: 2 651 735

Volum Korrelasjon

Lang: 0.01 (neutral)

Kort: -0.83 (strong negative)

Signal:(43.07) Neutral

Lexaria Bioscience Corp. Korrelasjon

10 Mest positive korrelasjoner
RMRM	0.854
AKU	0.828
GAINL	0.828
LPLA	0.824
UNB	0.822
LMST	0.821
OCFC	0.809
SFBC	0.807
EFSC	0.807
LBAI	0.806

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Lexaria Bioscience Corp. Korrelasjon - Valuta/Råvare

0.49
( neutral )

0.69
( moderate )

0.20
( neutral )

0.04
( neutral )

-0.61
( weak negative )

Lexaria Bioscience Corp. Økonomi

Annual	2023
Omsetning:	$226 208
Bruttogevinst:	$194 708 (86.07 %)
EPS:	$-1.010

FY	2023
Omsetning:	$226 208
Bruttogevinst:	$194 708 (86.07 %)
EPS:	$-1.010

FY	2022
Omsetning:	$255 397
Bruttogevinst:	$183 556 (71.87 %)
EPS:	$-1.240

FY	2021
Omsetning:	$722 738
Bruttogevinst:	$547 392 (75.74 %)
EPS:	$-0.950

Financial Reports:

No articles found.

Lexaria Bioscience Corp.

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.